Cardiovascular safety of proton pump inhibitors in post-percutaneous coronary intervention patients receiving dual antiplatelet therapy: A meta-analysis

doi:10.4330/wjc.v18.i5.119100

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 5

This Article

Google Scholar

(0) (0) (0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (42)

All Articles published online

Item

Count

PDF

HTML

Figures (1-6)

Tables (1-2)

Sum=61

Publishing Process of This Article

Item

Count

Browse

Download

Sum=31

May 26, 2026 (publication date) through May 19, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Cardiol. May 26, 2026; 18(5): 119100
Published online May 26, 2026. doi: 10.4330/wjc.v18.i5.119100

Table 1 Study design of included studies

Ref.	Year	Country	Type of study	Total patients (n)	Study group (n)	Control group (n)	PPI used	Duration of study
Wei et al[9]	2016	China	RCT	207	123	84	Pantoprazole 40 mg	6 months
Vaduganathan et al[10]	2016	Spain and United States	RCT	2676	870	1806	Omeprazole 20 mg	110 days
Ren et al[11]	2011	Chinese	RCT	172	86	86	Omeprazole	30 days
Jensen et al[12]	2017	Denmark	RCT	2009	870	1806	Pantoprazole	1 year
Kim et al[13]	2024	Korea	Retrospective	2266	1133	1133	Non-selective PPI	15 years
Rossini et al[14]	2011	Italy	Retrospective	1328	1158	170	Non-selective PPI	12 months
Yasu et al[15]	2010	Japan	Retrospective	302	103	199	Rabeprazole	395 days
Aihara et al[16]	2012	Japan	Retrospective	1000	500	500	Non-selective PPI	1 year
Chandrasekhar et al[17]	2017	United States and Europe	Retrospective	4635	1062	3573	Non-selective PPI	24 months

RCT: Randomized controlled trial; PPI: Proton pump inhibitor.

Full Size Table

Table 2 Baseline characteristics of included population, mean ± SD/n (%)

Ref.	Age		Male gender		Hypertension		Diabetes mellitus
Ref.	Study group (years)	Control group (years)	Study group	Control group	Study group	Control group	Study group	Control group
Vaduganathan et al[10], 2016	NA	NA	NA	NA	NA	NA	NA	NA
Wei et al[9], 2016	59.32 ± 9.14	58.47 ± 10	69 (56.1)	48 (57.1)			502 (50.4)	496 (49.0)
Yasu et al[15], 2010	69.9 ± 9.6	67.4 ± 10.1	69 (67.0)	144 (72.4)	66 (64.1)	129 (64.8)	70 (68.0)	115 (57.8)
Kim et al[13], 2024	65.1 ± 11.2	65.6 ± 11.2	754 (66.5)	745 (65.8)	677 (59.8)	705 (62.2)	762 (65.8)	128 (72.5)
Jensen et al[12], 2017	64.7 ± 10.2	64.8 ± 10.6	729 (73.1)	758 (74.9)	535 (53.7)	546 (54.0)	113 (11.3)	103 (10.2)
Rossini et al[14], 2011	64 ± 11	63 ± 11	875 (75.6)	138 (81.2)	736 (63.6)	111 (65.2)	14338 (40.3)	13975 (39.3)
Ren et al[11], 2011	62.08 ± 10.62	61.84 ± 11.21	62	63			415 (83)	419 (83.8)
Aihara et al[16], 2012	68 ± 11	69 ± 10	363 (72.6)	379 (75.8)	356 (71.2)	345 (69.0)	205 (61.9)	579 (61.7)
Chandrasekhar et al[17], 2017	65.4 ± 11.1	64.1 ± 11.4	2686 (75.2)	738 (69.5)	847 (79.8)	2873 (80.4)	349 (32.9)	1171 (32.8)

NA: Not available.

Full Size Table

Citation: Sohail R, Khan Z, Shah HH, Khattak R, Khan A, Chaudhry S, Khan U, Mansoor H, Namal F, Orciuolo J, Desai S, Singh M. Cardiovascular safety of proton pump inhibitors in post-percutaneous coronary intervention patients receiving dual antiplatelet therapy: A meta-analysis. World J Cardiol 2026; 18(5): 119100
URL: https://www.wjgnet.com/1949-8462/full/v18/i5/119100.htm
DOI: https://dx.doi.org/10.4330/wjc.v18.i5.119100

Sohail R, Khan Z, Shah HH, Khattak R, Khan A, Chaudhry S, Khan U, Mansoor H, Namal F, Orciuolo J, Desai S, Singh M. Cardiovascular safety of proton pump inhibitors in post-percutaneous coronary intervention patients receiving dual antiplatelet therapy: A meta-analysis. World J Cardiol 2026; 18(5): 119100 [DOI: 10.4330/wjc.v18.i5.119100]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.